MONTREAL, November 25, 2021 – The 2021 ADRIQ biopharmaceutical sector RSRI award was presented to Feldan Therapeutics, a Quebec City-based company that CQDM has been funding since 2018 as part of a collaborative research project. This project brought together a group of five major pharmaceutical companies, the Quebec biotech Feldan and academic institutions to validate and advance the Feldan Shuttle, a promising technology for intracellular delivery of therapeutic compounds.
Thanks to the support provided by CQDM and its close collaboration with Frédéric Calon (Laval University), Frédéric Couture (TransBIOTech) as well as Amgen, GSK, Janssen, Sanofi and Takeda, Feldan has demonstrated that the Feldan Shuttle can deliver biologically active products into animal model cells, a feature that distinguishes the platform from competing technologies.
The outstanding results generated by this collaboration have allowed Feldan to complete critical preclinical validation milestones confirming the efficacy and safety of its technology. The project has significantly increased the potential value of the technology and Feldan will be in good position to launch its next round of equity financing and form strategic partnerships with key players in the pharmaceutical industry.
“Congratulations to Feldan Therapeutics and its CEO, François-Thomas Michaud, for taking this technology to new heights. This project exemplifies CQDM’s collaborative model which provides tremendous financial leverage for the benefit of local companies and the Quebec economy,” said Diane Gosselin, President and CEO of CQDM.
CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-leading pharmaceutical organizations, several Canadian biotech companies, the best researchers from the public and private sectors, as well as the Canadian and Quebec governments. CQDM’s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. Information – Website: cqdm.org, LinkedIn and Twitter.
About Feldan Therapeutics Inc.
Feldan is a biopharmaceutical company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan is behind the design of a proprietary peptide-based technology (Feldan Shuttle) that enables safe and efficient delivery of various compounds inside cells. The Feldan Shuttle unlocks the development of a new generation of therapeutics by providing access to intracellular components that are largely beyond the reach of existing drugs. Feldan develops treatments for lung and skin diseases and its treatment for nevoid basal-cell carcinoma syndrome (NBCCS) is currently in preclinical development. For more information: www.feldan.com.
*ADRIQ: Association pour le développement de la recherche et de l’innovation du Québec
For more information:
Head of Communications and Marketing